Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 ,inter alia, to consider and approve Pursuant to Regulation ....
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on Monday, November 3, 2025. The main agenda is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Q2 and H1 of FY26). This is a standard regulatory filing under SEBI's Listing Obligations rules. The company also reminded the exchanges that the trading window for its securities remains closed until November 5, 2025, which is normal practice during the results preparation period.
This is a routine pre-results announcement and does not by itself move the stock. Investors should watch for the actual Q2/H1 FY26 results, which will be declared on or after November 3, 2025 and could influence the share price based on performance versus expectations.